Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 6/2015

01-11-2015 | Original Article

A meta-analysis on concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to detect HER2 gene overexpression in breast cancer

Authors: Fatemeh Bahreini, Ali Reza Soltanian, Parvin Mehdipour

Published in: Breast Cancer | Issue 6/2015

Login to get access

Abstract

Background

We performed this meta-analysis study to evaluate the concordance and discordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) in detecting HER2 alteration in human breast cancer.

Methods

As a meta-analysis, the present study evaluated the available data from previous studies on the HER2 gene detected by IHC and FISH. To indicate the meta-analysis results, a forest plot was used.

Results

We identified 172 citations, for which our inclusion criteria were met by 18 articles, representing 6629 cases. The overall concordance and discordance rate between IHC staining with score 0/1+ and FISH for detection failure of HER2 expression was 96 and 4 %, respectively. The present study showed that the overall proportion of FISH positive and negative rate for IHC score 2+ for detection of HER2 expression was 36 and 64 %, respectively; and 91 and 9 % for 3+ IHC scores.

Conclusion

The results of this study show that IHC score 0/1+ and 3+ cannot be completely considered as negative and positive breast cancer test, respectively. Therefore, we suggest a valid and complementary test, the same as FISH, to explore HER2 expression.
Literature
1.
Pauletti G, Dandekar S, Rong H, Ramos L, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000;18(21):3651–64.PubMed
2.
Muss HB, Thor-Ann D, Berry-Donald A, et al. C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994;330:1260–6.CrossRefPubMed
3.
Soonmyung P, John B, Chanheun P, et al. ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst. 1998;90(18):1361–70.CrossRef
4.
Eichhorn Pieter JA, José B. HER2 Signatures in breast cancer: ready to go to print? Am Soc Clin Oncol. 2010;28(11):1809–10.CrossRef
5.
Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707–12.CrossRefPubMed
6.
Dowsett M, Bartlett J, Ellis IO, et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centers. J Pathol. 2003;199:418–23.CrossRefPubMed
7.
Perez Edith A, Roche Patrick C, Jenkins Robert B, et al. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc. 2002;77:148–54.CrossRefPubMed
8.
Rhodes A, Sarson J, Assam E, et al. The reliability of rabbit monoclonal antibodies in the immunohistochemical assessment of estrogen receptors, progesterone receptors, and HER2 in human breast carcinomas. Am Soc Clin Pathol. 2010;134:621–32.CrossRef
9.
Alkushi A. Validation of tissue microarray biomarker expression of breast carcinomas in Saudi women. Hematol Oncol Stem Cell Ther. 2009;2(3):394–8.CrossRefPubMed
10.
Arens N, Bleyl U, Hildenbrand R. HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer. Virchows Arch. 2005;446:489–96.CrossRefPubMed
11.
Artufel MV, Valero AC, Lladó RR, et al. Molecular protocol for HER2/neu analysis in breast carcinoma. Clin Transl Oncol. 2005;7(11):504–11.CrossRefPubMed
12.
Bánkfalvi A, Boecker W, Reiner A. Comparison of automated and manual determination of HER2 status in breast cancer for diagnostic use: a comparative methodological study using the Ventana BenchMark automated staining system and manual tests. Int J Oncol. 2004;25(4):929–35.PubMed
13.
Barberis M, Pellegrini C, Cannone M, et al. Quantitative PCR and HER2 testing in breast cancer. Am J Clin Pathol. 2008;1(29):563–70.CrossRef
14.
Bishop JW, Marcelpoil R, Schmid J. Machine scoring of Her2/neu immunohistochemical stains. Anal Quant Cytol Histol. 2002;24(5):257–62.PubMed
15.
Bouché O, Penault-Llorca F. HER2 and gastric cancer: a novel therapeutic target for trastuzumab. Bull Cancer. 2010;97(12):1429–40.PubMed
16.
Burgea CN, Changb HR, Apple SK. Do the histologic features and results of breast cancer biomarker studies differ between core biopsy and surgical excision specimens? Breast. 2006;15:167–72.CrossRef
17.
Carlsson J, Nordgren H, Sjostrom J, et al. HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer. 2004;90:2344–8.PubMedCentralPubMed
18.
Saranya C, Stacie J, Lisa J, et al. Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancer. Clin Breast Cancer. 2010;10(1):40–5.CrossRef
19.
Conlin AK, Seidman AD, Bach A, et al. Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. Clin Breast Cancer. 2010;10(4):281–7.CrossRefPubMed
20.
Dank M. Human recombinant anti-HER2 monoclonal antibody—a new targeted treatment in breast cancer. Orv Hetil. 2001;142(46):2563–8.PubMed
21.
Shaheenah D, Gonzalez-Angulo Ana M, Florentia P, et al. Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin. Cancer. 2007;110(6):1195–200.CrossRef
22.
Raihanatou D, Karl-Ludwig S, Agnes B, et al. Secretory carcinoma of the breast: a distinct variant of invasive ductal carcinoma assessed by comparative genomic hybridization and immunohistochemistry. Hum Pathol. 2003;34(12):1299–305.CrossRef
23.
Erinn DK, Brian JY, Mark S, et al. The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast. Am J Surg Pathol. 2005;29:1221–7.CrossRef
24.
Dowsett M, Procter M, McCaskill-Stevens W, et al. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA trial. J Clin Oncol. 2009;27:2962–9.PubMedCentralCrossRefPubMed
25.
Egervari K, Szollosi Z, Nemes Z. Immunohistochemical antibodies in breast cancer HER2 diagnostics. A comparative immunohistochemical and fluorescence in situ hybridization study. Tumour Biol. 2008;29(1):18–27.CrossRefPubMed
26.
Kristof E, Zoltan S, Zoltan N. Re: a new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility. Appl Immunohistochem Mol Morphol. 2008;16(5):510–1.CrossRef
27.
Kristof E, Zoltan S, Zoltan N. Tissue microarray technology in breast cancer HER2 diagnostics. Pathol Res Pract. 2007;203:169–77.CrossRef
28.
Fitzgibbons PL, Murphy DA, Dorfman DM, et al. Interlaboratory comparison of immunohistochemical testing for HER2. Arch Pathol Lab Med. 2006;130:1440–5.PubMed
29.
Yimin G, Nour S, Eltorky MA, et al. Immunohistochemical characterization of subtypes of male breast carcinoma. Breast Cancer Res. 2010;11(3):1–8.
30.
Hanley KZ, Birdsong GG, Cohen C, et al. Immunohistochemical detection of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast carcinomas. Cancer Cytopathol. 2009;117:279–88.CrossRef
31.
Hayes DF, Thor AD, Dressler LG, et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2007;357:1496–506.CrossRefPubMed
32.
Ivković-Kapicl T, Knezević-Usaj S. Human epidermal growth factor receptor 2 testing in breast cancer. Med Pregl. 2010;63(1–2):69–74.CrossRefPubMed
33.
Jørgensen JT, Møller S, Rasmussen BB, et al. High concordance between two companion diagnostics tests: a concordance study between the HercepTest and the HER2 FISH pharmDx kit. Am J Clin Pathol. 2011;136(1):145–51.CrossRefPubMed
34.
Kounelis S, Kapranos N, Malamos N, et al. Evaluation of HER2 gene status in breast cancer by chromogenic in situ hybridization: comparison with immunohistochemistry. Anticancer Res. 2005;25(2A):939–46.PubMed
35.
Kovacs A, Stenman G. HER2-testingin 538 consecutive breast cancer cases using FISH and immunohistochemistry. Pathol Res Pract. 2010;206:39–42.CrossRefPubMed
36.
Latta EK, Tjan S, Parkes RK, et al. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Mod Pathol. 2002;15(12):1318–25.CrossRefPubMed
37.
Lewis F, Jackson P, Lane S, et al. Testing for HER2 in breast cancer. Histopathology. 2004;45:207–17.CrossRefPubMed
38.
Lidgren M, Jonsson B, Rehnberg C, et al. Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer. Ann Oncol. 2008;19:487–95.CrossRefPubMed
39.
Liu JJ, Shen R, Chen L, et al. Piwil2 is expressed in various stages of breast cancers and has the potential to be used as a novel biomarker. Int J Clin Exp Pathol. 2010;3(4):328–37.PubMedCentralPubMed
40.
Liu YH, Xu FP, Rao JY, et al. Justification of the change from 10% to 30% for the immunohistochemical HER2 scoring criterion in breast cancer. Am J Clin Pathol. 2009;132:74–9.CrossRefPubMed
41.
López-Guerrero JA, Navarro S, Noguera R, et al. Histological tumor grade correlates with HER2/c-erB-2 status in invasive breast cancer: a comparative analysis between immunohistochemical (CB11 clone and Herceptest), FISH and differential PCR procedures. Arkh Patol. 2003;65(1):50–5.PubMed
42.
Loring P, Cummins R, O’Grady A, et al. HER2 positivity in breast carcinoma: a comparison of chromogenic in situ hybridization with fluorescence in situ hybridization in tissue microarrays, with targeted evaluation of intratumoral heterogeneity by in situ hybridization. Appl Immunohistochem Mol Morphol. 2005;13(2):194–200.CrossRefPubMed
43.
Manion E, Hornick JL, Lester SC, et al. A comparison of equivocal immunohistochemical results with anti- HER2/neu antibodies A0485 and SP3 with corresponding FISH results in routine clinical practice. Am J Clin Pathol. 2011;135(6):845–51.CrossRefPubMed
44.
Miguel M, Alvaro RL, Amparo R, et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Res Treat. 2010;123:149–57.CrossRef
45.
Morelle M, Haslé E, Treilleux I, et al. Cost-effectiveness analysis of strategies for HER2 testing of breast cancer patients in France. Int J Technol Assess Health Care. 2006;22(3):396–401.CrossRefPubMed
46.
Ni R, Mulligan AM, Have C, et al. PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/neu) status in breast cancer. Appl Immunohistochem Mol Morphol. 2007;15:316–24.CrossRefPubMed
47.
Ogrady A, Allen D, Happerfield L, et al. An immunohistochemical and fluorescence in situ hybridization-based comparison between the OracleHER2 bond immunohistochemical system, Dako HercepTest, and Vysis PathVysion HER2 FISH using both commercially validated and modified ASCO/CAP and United Kingdom HER2 IHC scoring guidelines. Appl Immunohistochem Mol Morphol. 2010;18:489–93.CrossRef
48.
Palacios J, Honrado E, Osorio A, et al. Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers. Breast Cancer Res Treat. 2005;90:5–14.CrossRefPubMed
49.
Penault-Liorca F, Bilous M, Dowsett M, et al. Emerging technologies for assessing HER2 amplification. Am J Clin Pathol. 2009;132:539–48.CrossRef
50.
Pritchard KI, Shepherd LE, O’Malley FP, et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med. 2006;354:2103–11.CrossRefPubMed
51.
Ratcliffe N, Wells W, Wheeler K, et al. The combination of in situ hybridization and immunohistochemical analysis: an evaluation of Her2/neu expression in paraffin embedded breast carcinomas and adjacent normal-appearing breast epithelium. Mod Pathol. 1997;10(12):1247–52.PubMed
52.
Socorro-Marıa RP, Yolanda RG, Gema MB, et al. Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype. Am J Surg Pathol. 2007;31:501–8.CrossRef
53.
Rody A, Karn T, Gätje R, et al. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophosphamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures. Zentralbl Gynakol. 2006;128(2):76–81.CrossRefPubMed
54.
Ryden L, Haglund M, Bendahl PO, et al. Reproducibility of human epidermal growth factor receptor 2 analysis in primary breast cancer: a National survey performed at pathology departments in Sweden. Acta Oncol. 2009;48:860–6.PubMed
55.
Ryden L, Jirstrom K, Haglund M, et al. Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up. Breast Cancer Res Treat. 2010;120:491–8.CrossRefPubMed
56.
Schaller G, Evers K, Papadopoulos S, et al. Current use of HER2 tests. Ann Oncol. 2001;12(1):S97–100.CrossRefPubMed
57.
Shabaik A, Lin G, Peterson M, et al. Reliability of Her2/neu, estrogen receptor, and progesterone receptor testing by immunohistochemistry on cell block of FNA and serous effusions from patients with primary and metastatic breast carcinoma. Diagn Cytopathol. 2011;39(5):328–32.CrossRefPubMed
58.
Striebel JM, Bhargava R, Horbinski C, et al. The equivocally amplified HER2 FISH result on breast core biopsy: indications for further sampling do affect patient management. Am J Clin Pathol. 2008;129(3):383–90.CrossRefPubMed
59.
60.
Vlasoff DM, Baschinsky DY, De Young BR, et al. C-erb B2 (Her2/neu) is neither overexpressed nor amplified in hepatic neoplasms. Appl Immunohistochem Mol Morphol. 2002;10(3):237–41.PubMed
61.
Carlson RW, Moench SJ, Hammond ME, et al. HER2 testing in breast cancer: NCCN Task Force report and recommendations. JNCCN. 2006;4(3):S1–22.
62.
Cho EY, Srivastava A, Park K, et al. Comparison of four immunohistochemical tests and FISH for measuring HER2 expression in gastric carcinomas. Pathology. 2012;44(3):216–20.CrossRefPubMed
63.
Fountzilas G, Dafni U, Bobos M, et al. Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel. PLoS ONE. 2012;7(6):e37946.PubMedCentralCrossRefPubMed
64.
Jacobs TW, Gown AM, Yaziji H, et al. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol. 1999;17(7):1974–80.PubMed
65.
Kakar S, Puangsuvan N, Stevens JM, et al. HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival. Mol Diagn. 2000;5(3):199–207.CrossRefPubMed
66.
Lambein K, Praet M, Forsyth R, et al. Relationship between pathological features, HER2 protein expression and HER2 and CEP17 copy number in breast cancer: biological and methodological considerations. J Clin Pathol. 2011;64(3):200–7.CrossRefPubMed
67.
Li HH, Ma F, Zeng X, et al. Comparison of fluorescence in situ hybridization and immunohistochemistry assessment for Her-2 status in breast cancer and its relationship to clinicopathological characteristics. Zhonghua Yi Xue Za Zhi. 2011;91(2):76–80.PubMed
68.
Minot DM, Voss J, Rademacher S, et al. Image analysis of HER2 immunohistochemical staining. Reproducibility and concordance with fluorescence in situ hybridization of a laboratory-validated scoring technique. Am J Clin Pathol. 2012;137(2):270–6.CrossRefPubMed
69.
Owens MA, Horten BC, Da-Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer. 2004;5(1):63–9.CrossRefPubMed
70.
Panjwani P, Epari S, Karpate A, et al. Assessment of HER-2/neu status in breast cancer using fluorescence in situ hybridization & immunohistochemistry: experience of a tertiary cancer referral centre in India. Indian J Med Res. 2010;132:287–94.PubMed
71.
Park YS, Hwang HS, Park HJ, et al. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use? Hum Pathol. 2012;43(3):413–22.CrossRefPubMed
72.
Pinhel I, Hills M, Drury S, et al. ER and HER2 expression are positively correlated in HER2 nonoverexpressing breast cancer. Breast Cancer Res Treat. 2012;14(2):R46.CrossRef
73.
Ramalho S, Serra KP, Vassallo J, et al. HER2 expression in Brazilian patients with estrogen and progesterone receptor-negative breast carcinoma. Acta Histochem 2012 (in press).
74.
Shigematsu H, Kadoya T, Kobayashi Y, et al. A case of HER-2-positive recurrent breast cancer showing a clinically complete response to trastuzumab-containing chemotherapy after primary treatment of triple-negative breast cancer. World J Surg Oncol. 2011;7(9):146.CrossRef
75.
Tafe LJ, Janjigian YY, Zaidinski M, et al. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization. Arch Pathol Lab Med. 2011;135(11):1460–5.CrossRefPubMed
76.
Tanner M, Gancberg D, Di-Leo A, et al. Technical advance. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol. 2000;157(5):1467–72.PubMedCentralCrossRefPubMed
77.
Thomson TA, Hayes MM, Spinelli JJ, et al. HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod Pathol. 2001;14(11):1079–86.CrossRefPubMed
78.
Tvrdík D, Stanek L, Skálová H, et al. Comparison of the IHC, FISH, SISH and qPCR methods for the molecular diagnosis of breast cancer. Mol Med Report. 2012;6(2):439–43.
79.
Varga Z, Tubbs RR, Wang Z, et al. Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancer. Breast Cancer Res Treat. 2012;132(3):925–35.CrossRefPubMed
80.
Wang S, Saboorian MH, Frenkel E, et al. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol. 2000;53:374–81.PubMedCentralCrossRefPubMed
81.
Yosepovich A, Avivi C, Bar J, et al. Breast cancer HER2 equivocal cases: is there an alternative to FISH testing? A pilot study using two different antibodies sequentially. Isr Med Assoc J. 2010;12(6):353–6.PubMed
82.
Brown LD, Cai TT. Interval estimation for a binomial proportion. Stat Sci. 2001;16(2):101–33.
83.
Lebeau A, Deimling D, Kaltz C, et al. HER-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol. 2001;19(2):354–63.PubMed
84.
McCormick SR, Lillemoe TJ, Beneke J, et al. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization. Am J Clin Pathol. 2002;117:935–43.CrossRefPubMed
85.
Ellis CM, Dyson MJ, Stephenson TJ, et al. HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques. J Clin Pathol. 2005;58:710–4.PubMedCentralCrossRefPubMed
86.
Ainsworth R, Bartlett JMS, Going JJ, et al. IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTestTM in breast carcinoma. J Clin Pathol. 2005;58:1086–90.PubMedCentralCrossRefPubMed
87.
Dybdal N, Leiberman G, Anderson S, et al. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat. 2005;93:3–11.CrossRefPubMed
88.
Sapino A, Marchiò C, Senetta R, et al. Routine assessment of prognostic factors in breast cancer using a multicore tissue microarray procedure. Virchows Arch. 2006;449:288–96.CrossRefPubMed
89.
Bergqvista J, Elmbergera G, Ohdb J, et al. Activated ERK1/2 and phosphorylated oestrogen receptor a are associated with improved breast cancer survival in women treated with tamoxifen. Eur J Cancer. 2006;42:1104–12.CrossRef
90.
Powell WC, Hicks DG, Prescott N, et al. A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility. Appl Immunohistochem Mol Morphol. 2007;15(1):94–102.CrossRefPubMed
91.
Drev P, Grazio SF, Bracko M. Tissue microarrays for routine diagnostic assessment of HER2 status in breast carcinoma. Appl Immunohistochem Mol Morphol. 2008;16(2):179–84.CrossRefPubMed
92.
Umemura S, Osamura RY, Akiyama F, Honma K, et al. What causes discrepancies in HER2 testing for breast cancer? Am J Clin Pathol. 2008;130:883–91.CrossRefPubMed
93.
Gilbert JA, Goetz MP, Reynolds CA, et al. Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy. Mol Cancer Ther. 2008;7:944–51.PubMedCentralCrossRefPubMed
94.
Vegt B, Bock GH, Bart JZNG, et al. Validation of the 4B5 rabbit monoclonal antibody in determining Her2/neu status in breast cancer. Mod Pathol. 2009;22:879–86.CrossRefPubMed
95.
Rhodes A, Sarson J, Assam E, et al. The reliability of rabbit monoclonal antibodies in the immunohistochemical assessment of estrogen receptors, progesterone receptors, and HER2 in human breast carcinomas. Am J Clin Pathol. 2010;134:621–32.CrossRefPubMed
96.
Grimm EE, Schmidt RA, Swanson PE, et al. Achieving 95% cross-methodological concordance in HER2 testing. Am J Clin Pathol. 2010;134:284–92.CrossRefPubMed
97.
Dowsett M, Cooke T, Ellis I, et al. Assessment of HER2 status in breast cancer: why, when and how? Eur J Cancer. 2000;36:170–6.CrossRefPubMed
98.
Horiguchi S, Hishima T, Hayashi Y, et al. HER-2/neu cytoplasmic staining is correlated with neuroendocrine differentiation in breast carcinoma. J Med Dent Sci. 2010;57:155–63.PubMed
99.
Vogel UF. Confirmation of a low HER2 positivity rate of breast carcinomas-limitations of immunohistochemistry and in situ hybridization. Diagn Pathol. 2010;5:50–8.PubMedCentralPubMed
Metadata
Title
A meta-analysis on concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to detect HER2 gene overexpression in breast cancer
Authors
Fatemeh Bahreini
Ali Reza Soltanian
Parvin Mehdipour
Publication date
01-11-2015
Publisher
Springer Japan
Published in
Breast Cancer / Issue 6/2015
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-014-0528-0

Other articles of this Issue 6/2015

Breast Cancer 6/2015 Go to the issue

Original Article

Epidemiology of ductal carcinoma in situ in Western Australia: implications for surgical margins and management

Original Article

EIF5A2 is a novel chemoresistance gene in breast cancer

Acknowledgment

Acknowledgement to reviewers 2015

Original Article

Histological findings of an autologous dermal fat graft implanted onto the pectoralis major muscle of a rat model

Original Article

Fatigue in breast cancer patients: psychometric evaluation of the fatigue questionnaire EORTC QLQ-FA13

Original Article

Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits